Fecal Microbiota Transplant As Treatment of Hepatic Encephalopathy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Hepatic Encephalopathy
Interventions
DRUG

Fecal Microbiota Transplant (FMT) oral capsules

Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.

DRUG

Placebo oral capsule

Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Center for Microbiome Informatics and Therapeutics

UNKNOWN

lead

Massachusetts General Hospital

OTHER

NCT03420482 - Fecal Microbiota Transplant As Treatment of Hepatic Encephalopathy | Biotech Hunter | Biotech Hunter